Chene Bougeries

Researchers are investigating whether tailored axillary surgery TAS combined with axillary radiotherapy ART is better than the current standard treatment, axillary lymph node dissection ALND, for patients with clinically node-positive breast cancer undergoing upfront surgery. The study aims to see if TAS plus ART improves arm-related quality of life and reduces the occurrence of lymphedema two years after treatment. This question arises because ALND, although standard, can cause significant side effects, and TAS selectively targets affected lymph nodes with potentially less harm. Participants will be randomly assigned to one of two groups one receiving ALND, which involves removing lymphatic tissue within the axilla, and the other receiving TAS with ART, where surgery removes sentinel and suspicious lymph nodes followed by targeted axillary radiotherapy. All participants will also receive breast or chest wall irradiation after breast-conserving surgery. The study compares these approaches to assess their impact on arm health and quality of life. During the trial, participants will be followed for at least two years to assess changes in arm-related quality of life and monitor for lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations over this period. The study is sponsored by University Hospital Basel and aims to complete primary outcome assessments by the end of 2029, with overall study completion planned for 2037.

Researchers are investigating whether adding a new medicine called tirzepatide, a glucose-dependent insulinotropic polypeptide GIPglucagon-like peptide-1 receptor agonist GLP-1RA, to usual insulin therapy can improve blood sugar control in adults with type 1 diabetes T1D. The study is designed as a prospective, randomized clinical trial to evaluate this combinations effect on glucose management, aiming to provide new options beyond standard insulin treatment. About 30% of adults with T1D currently meet recommended blood sugar targets, highlighting the need for improved therapies. The study will enroll adults aged 18 to 65 years with T1D diagnosed for at least 12 months who are already using automated insulin delivery AID systems. Participants will be randomly assigned to either continue their standard care or to add once-weekly injections of tirzepatide, starting at a low dose of 2.5 mg and increasing to 5 mg weekly for 12 weeks. The trial includes a 4-week dose titration phase followed by 12 weeks of treatment, comparing glucose control outcomes between groups. Participants will wear a continuous glucose monitor CGM and share their glucose and insulin data throughout the 16-week study. Researchers will assess time spent within target glucose ranges, changes in blood sugar levels, insulin doses, and body weight. Safety and adherence will be monitored during the trial. The study aims to gather important data on whether tirzepatide can help improve glucose control and quality of life for adults living with T1D.